Inventor · disambiguated record
Christina Claus
Also filed as: CLAUS CHRISTINA
13 granted patents·21 pending applications·143 citations·filing 2016–2025
91Inventor score
Top patents by PatentIndex Score
34 records- 0197US11306154B2Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Apr 19, 2022·13 cites·56 claims
- 0297US11267903B2Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Mar 8, 2022·17 cites·46 claims
- 0397US10464981B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Nov 5, 2019·33 cites·22 claims
- 0496US11447558B2Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9HOFFMANN LA ROCHE·Filed 2019·Granted Sep 20, 2022·14 cites·22 claims
- 0596US10392445B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Aug 27, 2019·31 cites·39 claims
- 0695US11149083B2Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moietyHOFFMANN—LA ROCHE INC·Filed 2018·Granted Oct 19, 2021·12 cites·25 claims
- 0795US10526413B2Bispecific antibodies specific for OX40HOFFMANN LA ROCHE·Filed 2016·Granted Jan 7, 2020·23 cites·20 claims
- 0887US2025101135A1Antigen binding molecules comprising a tnf family ligand trimerHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 0980US12441812B2Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding moleculesHOFFMANN LA ROCHE·Filed 2022·Granted Oct 14, 2025·0 cites·28 claims
- 1076US2025066448A1Her2-targeting antigen binding molecules comprising 4-1bblHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1175US12202870B2Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereofHOFFMANN LA ROCHE·Filed 2021·Granted Jan 21, 2025·0 cites·40 claims
- 1270US12240911B2Bispecific antibodies specific for OX40HOFFMANN LA ROCHE·Filed 2019·Granted Mar 4, 2025·0 cites·20 claims
- 1369US2023045262A1Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9HOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1468US2022073646A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1567US12065478B2HER2-targeting antigen binding molecules comprising 4-1BBLHOFFMANN LA ROCHE·Filed 2020·Granted Aug 20, 2024·0 cites·11 claims
- 1666US12281153B2Combination therapy with targeted 4-1BB (CD137) agonistsHOFFMANN LA ROCHE·Filed 2020·Granted Apr 22, 2025·0 cites·24 claims
- 1766US2023123178A1Antigen Binding Molecules comprising a TNF family ligand trimer and PD1 binding moietyHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1866US2020270321A1Antigen binding molecules comprising a trimeric tnf family ligandHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 1963US2025340614A1Combination therapy with targeted 4-1bb (cd137) agonistsHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 2061US2024043535A1IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULESHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2161US2021009656A1C-terminally fused tnf family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2261US2023086210A14-1bbl trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2360US2019194291A1C-terminally fused tnf family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 2459US2022267464A1Fusion of an antibody binding cea and 4-1bblHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2558US2022025069A1Bispecific antigen binding molecules comprising lipocalin muteinsHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2657US2019211113A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 2756US2020325225A1Combination therapy with targeted 4-1bb (cd137) agonistsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2856US2024092856A1Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2955US2019185566A1Antigen Binding Molecules comprising a TNF family ligand trimer and PD1 binding moietyHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 3053US2021253724A1Novel bispecific agonistic 4-1bb antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3152US2020347115A1Novel tnf family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 3251US2017247467A1Bispecific antibodies with tetravalency for a costimulatory tnf receptorHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 3348US2019016771A1Trimeric costimulatory tnf family ligand-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 3442US11536716B2Cell based assay for determining antibody or ligand binding and functionHOFFMANN LA ROCHE·Filed 2016·Granted Dec 27, 2022·0 cites·26 claims
Join the waitlist — get patent alerts
Get an alert when Christina Claus files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →